NKX6-1 and nonpapillary renal cell carcinoma: Our approach has the potential to narrow master TFs to clinically meaningful ones and augments the current armamentarium with additional TFs, including BHLHE41 (ccRCC) and NKX6.1 (chRCC) that can be stained to better characterize tumors.